

Clinical Trial Design Considerations for Malaria Drug Development—June 30, 2016

Speakers and Panelists

Paul Arguin, M.D.

Chief, Domestic Response Unit, Malaria
Centers for Disease Control and Prevention, Atlanta, Georgia

Shukal Bala, Ph.D.

Microbiologist
Division of Anti-infective Products (DAIP), Office of Antimicrobial Products (OAP), Center for Drug Evaluation and Research (CDER)

Rana Chattopadhyay, Ph.D.

Biologist
Division of Vaccines and Related Product Applications, Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
Food and Drug Administration, Silver Spring, Maryland

Dakshina Chilukuri, Ph.D.

Pharmacologist
Office of Clinical Pharmacology, Office of Translational Sciences
Center for Drug Evaluation and Research (CDER)
Food and Drug Administration, Silver Spring, Maryland

Ingrid Felger, Ph.D.

Head, Molecular Diagnostics Unit
Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland

Noel Gerald, Ph.D.

Biologist
Division of Microbiology Devices, Office of In Vitro Diagnostics and Radiological Health,
Center for Devices and Radiological Health
Food and Drug Administration, Silver Spring, Maryland

Karen Higgins, Sc.D.

Mathematical Statistician
DAIP, OAP, CDER
Food and Drug Administration, Silver Spring, Maryland

James Kublin, M.D., M.P.H.

Executive Director of the HIV Vaccine Trials Network
Medical Director of the Seattle Malaria Clinical Trials Center
Fred Hutchinson Cancer Research Center, Seattle, Washington

Matthew Laurens, M.D., M.P.H.

Director, International Clinical Trials Unit, Division of Malaria Research
Institute for Global Health
University of Maryland School of Medicine, Baltimore, Maryland

James McCarthy, M.D.

Senior Scientist
Queensland Institute of Medical Research (QIMR), Berghofer Medical Research Institute
Brisbane, Australia

Jörg Möhrle, Ph.D., M.B.A.

Vice President, Head of Translational Medicine
Medicines for Malaria Venture, Geneva, Switzerland

Sean Murphy, M.D., Ph.D.

Assistant Professor and Assistant Director of Clinical Microbiology
University of Washington, Seattle, Washington

Sumathi Nambiar, M.D., M.P.H.

Director
DAIP, OAP, CDER
Food and Drug Administration, Silver Spring, Maryland

Elizabeth O'Shaughnessy, M.D.

Medical Officer
DAIP, OAP, CDER
Food and Drug Administration, Silver Spring, Maryland

Michael Proschan, Ph.D.

Mathematical Statistician
National Institute of Allergy and Infectious Diseases. Rockville, MD

David Saunders, M.D., M.P.H.

Clinical Pharmacologist and Internist
US Army Medical Materiel Development Activity, Fort Detrick, Maryland

Bryan Smith, M.D.

Principal Medical Consultant
Clinical Network Services, Washington, DC

Kalavati Suvarna, Ph.D.

Microbiologist
DAIP, OAP, CDER
Food and Drug Administration, Silver Spring, Maryland

Peter Weina, M.D., Ph.D.

Chief, Department of Research Programs
Walter Reed National Military Medical Center, Washington, DC

Tim Wells, Ph.D.

Chief Scientific Officer
Medicines for Malaria Venture, Geneva, Switzerland

Disclosures

Dr. Smith is a full time employee of Clinical Network Services (USA), Inc. Dr. Smith is the Chief Medical Officer of 60 Degrees Pharmaceutical, LLC

Dr McCarthy has received funding from Novartis and Sanofi to support clinical trials.

Dr. Murphy has served as a consultant to Biofire Defense and has received clinical trial support from Novartis.

Dr. Möhrle is a full-time employee of Medicines for Malaria Venture (MMV).

Dr. Wells is a full-time employee of Medicines for Malaria Venture (MMV). He is also a non-executive director of Kymab, a biotechnology company in Cambridge, UK which specializes in the development of monoclonal antibodies and which collaborates with the Bill and Melinda Gates foundation on several disease areas including malaria and HIV.